Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals has announced a public offering of 8,474,577 common shares and 1,694,915 pre-funded warrants, priced at $29.50 and $29.4999 respectively. The offering aims to raise approximately $300 million in gross proceeds, which will support the company's clinical stage developments. The offering is set to close on or about October 8, 2021. The underwriters have a 30-day option to purchase an additional 1,525,423 shares at the offering price. Jefferies, SVB Leerink, Stifel, and RBC Capital Markets are leading the offering.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has initiated an underwritten public offering of $250 million in common shares, with an option for underwriters to purchase an additional $37.5 million. The offering is made under an existing shelf registration statement filed with the SEC. Notably, this process is subject to market conditions, and completion is not guaranteed. Notable underwriters include Jefferies, SVB Leerink, Stifel, and RBC Capital Markets. The company emphasizes that no securities are being offered in Canada.
Xenon Pharmaceuticals (Nasdaq:XENE) reported promising results from its Phase 2b X-TOLE clinical trial for XEN1101, aimed at treating focal epilepsy. The trial showcased statistically significant reductions in monthly focal seizure frequency across all dose groups, with p-values under 0.001 for the 20 mg and 25 mg doses. A median reduction of 52.8% was noted for the highest dose, compared to 18.2% for placebo. The encouraging outcomes support XEN1101's efficacy and safety, with plans to collaborate with the FDA for expedited development and a long-term study extension now set for three years.
Xenon Pharmaceuticals (Nasdaq:XENE) will host a conference call and webcast on October 4, 2021, at 7:30 AM ET to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial. Investors can join the conference call by dialing (855) 779-9075 in the U.S. or (631) 485-4866 internationally, using conference ID number 4481713. The call will be available on the Xenon website for replay after the event. Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals announced a $10 million milestone payment from Neurocrine Biosciences after gaining regulatory approval for a clinical trial application in Europe. This payment includes $4.5 million in cash and a $5.5 million equity investment at a premium price of $19.9755 per share. Xenon collaborates with Neurocrine on NBI-921352, aimed at treating focal-onset seizures and SCN8A developmental and epileptic encephalopathy. Phase 2 trials for both conditions are expected to begin later in 2021, reflecting progress in epilepsy treatment options.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Dr. Christopher Kenney as Chief Medical Officer. Dr. Kenney will lead clinical development and medical affairs strategies for the company's neurology-focused therapeutic programs. CEO Ian Mortimer expressed optimism about Dr. Kenney's extensive experience in clinical development and neuroscience, especially as the company prepares for the topline data from its XEN1101 Phase 2b X-TOLE study, expected in late September to mid-October. Dr. Kenney has over 20 years of experience in the field, including roles at Cadent Therapeutics and Acorda Therapeutics.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its Q2 2021 financial results, revealing a net loss of $22.1 million, up from $0.2 million a year prior, primarily due to reduced revenue and increased expenses. Total revenue fell to $2.2 million from $13.4 million in Q2 2020. Cash and equivalents rose to $260.5 million, expected to fund operations into 2023. The company anticipates topline data from the Phase 2b XEN1101 X-TOLE trial by mid-October, a potential inflection point. Clinical trials for XEN496 and XEN007 are ongoing, with other partnered milestones expected in 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 12th Annual Wedbush PacGrow Healthcare Conference. The company will engage in one-on-one investor meetings and a virtual panel discussion titled “Got My Mind Set On You - Advancing Novel Epilepsy Targets.”
The panel is scheduled for August 11, 2021, from 11:30 am to 12 pm Eastern Time, featuring Dr. Simon Pimstone, Executive Chair of the Board. Interested parties can find further details and a link to the live webcast on the Investors section of Xenon's website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will announce its Q2 2021 financial results after the U.S. markets close on August 11, 2021. Management will hold a conference call and live audio webcast at 4:30 pm ET to discuss these results and provide corporate updates. Investors can access the webcast via the Xenon website. The details are subject to change, and webcasts will be available for replay after the event.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its upcoming participation in the virtual William Blair Biotech Focus Conference 2021. This event is scheduled for Thursday, July 15, 2021, from 10 am to 10:45 am Eastern Time. Key participants include Ian Mortimer, President and CEO, and Dr. Simon Pimstone, Executive Chair of the Board. For further details and a link to the live webcast, visit Xenon’s official website. Webcasts will be available for replay post-event for 30 days. Xenon is focused on developing innovative therapies for neurological disorders.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
